StoxSyngene International vs NATCO Pharma: share price & financials comparison
NSE: SYNGENE vs NATCOPHARM · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Syngene International vs NATCO Pharma at a glance
Syngene International (SYNGENE) has a market capitalisation of ₹17,936 Cr, against ₹14,507 Cr for NATCO Pharma (NATCOPHARM). Over the past year NATCO Pharma has returned -1.1%, compared with -31.3% for Syngene International. On valuation, NATCO Pharma trades at a lower P/E of 17.5 versus 469.5. NATCO Pharma earns a higher return on equity (8.5% vs 0.8%). Syngene International comes out ahead on financial health and technicals. NATCO Pharma comes out ahead on size, valuation, profitability and momentum. Across the scored metrics below, Syngene International leads on 5 and NATCO Pharma on 12. On StoxGud's 10-point checklist, Syngene International scores 3/10 and NATCO Pharma scores 5/10.
| Metric | Syngene International | NATCO Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹17,936 Cr | ₹14,507 Cr |
| Revenue (latest FY) | ₹3,739 Cr | ₹4,078 Cr |
| Net profit (latest FY) | ₹0 Cr | ₹1,418 Cr |
| Valuation | ||
| P/E | 469.5 | 17.5 |
| P/B | 3.69 | 1.49 |
| Dividend yield | 0.28% | 0.62% |
| Profitability | ||
| Return on equity | 0.8% | 8.5% |
| Net profit margin | 1.1% | 26.8% |
| Operating margin | 21.3% | 23.7% |
| Growth | ||
| Revenue growth (YoY) | -8.6% | -29.0% |
| Net profit growth (YoY) | — | -60.9% |
| Revenue CAGR (multi-year) | +11.3% | +14.7% |
| Financial health | ||
| Debt to equity | 0.01 | 0.11 |
| Momentum | ||
| 1-month return | +17.1% | +2.7% |
| 1-year return | -31.3% | -1.1% |
| 3-year CAGR | -14.4% | +0.7% |
| 5-year CAGR | -5.6% | -0.9% |
| 10-year CAGR | +5.1% | +2.2% |
| Distance from 52W high | -33.1% | -32.8% |
| Technicals | ||
| RSI (14) | 77 | 65 |
| Price vs 200-day avg | +5.4% | -12.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Syngene International | NATCO Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✗ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 3/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Syngene International or NATCO Pharma?
Syngene International has a market cap of ₹17,936 Cr and NATCO Pharma has a market cap of ₹14,507 Cr as of 13 Nov 2026.
Which has a lower P/E, Syngene International or NATCO Pharma?
NATCO Pharma has the lower P/E: Syngene International trades at 469.5 and NATCO Pharma at 17.5.
Which gave better returns in the last year, Syngene International or NATCO Pharma?
NATCO Pharma did better: Syngene International returned -31.3% and NATCO Pharma returned -1.1% over one year.
What is the difference between Syngene International and NATCO Pharma?
Both are NSE-listed companies in Healthcare. Syngene International is about 1.2 times the size of NATCO Pharma by market cap. In the latest financial year Syngene International reported revenue of ₹3,739 Cr and NATCO Pharma ₹4,078 Cr. Operating margin is 21.3% for Syngene International and 23.7% for NATCO Pharma. Debt to equity is 0.01 for Syngene International and 0.11 for NATCO Pharma.
Which is better, Syngene International or NATCO Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Syngene International leads on 5 and NATCO Pharma on 12. Syngene International is ahead on financial health and technicals. NATCO Pharma is ahead on size, valuation, profitability and momentum. On StoxGud's rules-based checklist Syngene International scores 3/10 and NATCO Pharma scores 5/10. This is information, not advice: consult a SEBI-registered adviser before investing.